Treasury Board of Canada Secretariat
www.tbs-sct.gc.ca
Common menu bar links
Breadcrumb Trail
ARCHIVED - Patented Medicine Prices Review Board Canada
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Section III — Supplementary Information
List of Supplementary Information Tables
The following tables are located on the Treasury Board Secretariat web site:
Sources of Non-Respendable Revenue (http://www.tbs-sct.gc.ca/rpp/st-ts-eng.asp)
Other Items of Interest
PMPRB Annual Report 2007 (http://www.pmprb-cepmb.gc.ca/English/View.asp?x=91&mp=68)
Quarterly NEWSletters (http://www.pmprb-cepmb.gc.ca/english/View.asp?x=287&mp=68)
Patentee’s Guide to Reporting (http://www.pmprb-cepmb.gc.ca/english/view.asp?x=146)
Compendium of Guidelines, Policies and Procedures
(http://www.pmprb-cepmb.gc.ca/english/view.asp?x=1034)
Patent Act (http://laws.justice.gc.ca/en/P-4/index.html)
Patented Medicines Regulations (http://laws.justice.gc.ca/en/P-4/SOR-94-688/index.html)
1 For program activity descriptions, please see Page 5.
2 Prior to 2009-2010, Internal services costs were distributed by Program Activities 1 and 2.
3 The PMPRB has only one Strategic Outcome (SO) (see page 7), and all priorities are linked to that SO. Links to Program Activity (PA) are indicated in this column.
4 Treasury Board approved authority to increase reference levels in Vote 35 (Program expenditures) by $5.6 million for 2009-2010. This funding will allow the Patented Medicine Prices Review Board to: 1) hold necessary hearings into excessive prices in a timely manner, as required by the Patent Act; 2) address the increase in workload anticipated as significantly more patented drug products sold by generic companies come under its jurisdiction; 3) modernize its Excessive Price Guidelines, to better deal with new forms of incremental pharmaceutical innovation; 4) replace its outdated data management system, which houses and manipulates all of the confidential sales and price information filed by patentees; 5) strengthen its policy and economic analysis capacity to better anticipate and respond to emerging and evolving developments in the regulatory environment and the pharmaceutical sector; and 6) maintain the timeliness of ongoing price reviews and investigations.
5 Class of customer: pharmacy, hospital, wholesaler, other.
6 Quebec does not participate.
